Schrödinger (SDGR) has drawn investor attention after recent share price moves, with the stock last closing at US$18.64. That ...
Earlier in December 2025, BofA Securities upgraded Schrödinger, Inc. after the company shifted away from internal drug development to concentrate on its core computational software business. This ...
Hosted on MSN
Schrodinger Downgraded By Citi After Ending Blood Cancer Drug Trial Tied To 2 Deaths; Retail Voices Concern
Schrodinger shares came under pressure after Citi pulled back its bullish call, cutting the stock to ‘Neutral’ from ‘Buy’ and slashing its price target to $20 from $35. The firm said recent stumbles ...
We recently published a list of 10 AI News And Ratings on Wall Street’s Radar. In this article, we are going to take a look at where Schrödinger, Inc. (NASDAQ:SDGR) stands against other AI news and ...
By Sneha S K Jan 9 (Reuters) - Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical ...
Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback